Prognostic value of PSA kinetics in locally advanced prostate cancer treated by maximal androgen blockade combined with brachytherapy.
- Author:
Yong LUO
;
Neng-Bao WEI
;
Jia-Hui ZHAO
;
Xin-Hao CUI
;
Ming-Chuan LI
;
Yun-Hua LIN
;
Zhu HOU
;
Yi-Li HAN
;
Yong-Guang JIANG
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Androgens; administration & dosage; therapeutic use; Brachytherapy; Humans; Male; Middle Aged; Prognosis; Prostate-Specific Antigen; metabolism; Prostatic Neoplasms; metabolism; therapy; Retrospective Studies
- From: National Journal of Andrology 2014;20(3):229-233
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the effect of post-treatment PSA kinetics on the prognosis of prostate cancer (PCa).
METHODSWe retrospectively reviewed the clinical data of 114 cases of locally advanced PCa treated by maximal androgen blockade (MAB) combined with brachytherapy, and analyzed the association of the changes in PSA kinetics with the prognosis of the patients.
RESULTSThe median survival time of the patients was 81 (15 - 144) months, with 1-, 3- and 5-year survival rates of 91. 23%, 78.07% and 68.42% , respectively. Univariate analysis indicated that the baseline PSA level, PSA nadir, the time of PSA decreasing to nadir, PSA doubling time, and the extent of PSA declining were all predictive factors for the survival time of the PCa patients. Multivariate analysis demonstrated that PSA nadir, the time of PSA decreasing to nadir, and the extent of PSA declining were three independent prognostic factors, which prolonged the long-term survival of the patients by 1.7, 3.2 and 6.8 times, respectively.
CONCLUSIONFor locally advanced PCa treated by MAB combined with brachytherapy, PSA nadir <1 micro g/L, the time to nadir <3 months, and the extent of PSA declining >96% are independent prognostic factors.